AnaptysBio (NASDAQ:ANAB) Raised to “Strong-Buy” at Wolfe Research

Wolfe Research upgraded shares of AnaptysBio (NASDAQ:ANAB) to a strong-buy rating in a report released on Monday, Marketbeat reports.

ANAB has been the subject of a number of other reports. Truist Financial dropped their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Wedbush reiterated an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a research note on Monday. Guggenheim reduced their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $19.00 target price on shares of AnaptysBio in a report on Tuesday. Finally, BTIG Research downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus target price of $40.08.

AnaptysBio Price Performance

Shares of ANAB stock opened at $16.06 on Monday. AnaptysBio has a one year low of $12.51 and a one year high of $41.31. The stock has a fifty day moving average price of $17.05 and a 200 day moving average price of $26.77. The stock has a market cap of $488.71 million and a P/E ratio of -2.64.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. Equities research analysts anticipate that AnaptysBio will post -6.08 EPS for the current year.

Insider Buying and Selling

In related news, Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were purchased at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 33.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its stake in AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 644 shares during the period. Algert Global LLC lifted its holdings in shares of AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 1,078 shares in the last quarter. Rhumbline Advisers boosted its position in shares of AnaptysBio by 3.8% during the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock worth $398,000 after buying an additional 1,111 shares during the period. nVerses Capital LLC grew its holdings in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in AnaptysBio in the 3rd quarter valued at approximately $49,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.